BACKGROUND: Although mechanisms for detection of short-term complications after blood transfusions are well developed, complications with delayed onset, notably transmission of chronic diseases such as cancer, have been difficult to assess. Our aim was to investigate the possible risk of cancer transmission from blood donors to recipients through blood transfusion. METHODS: We did a register-based retrospective cohort study of cancer incidence among patients who received blood from donors deemed to have a subclinical cancer at the time of donation. These precancerous donors were diagnosed with a cancer within 5 years of the donation. Data from all computerised blood bank registers in Sweden and Denmark gathered between 1968 and 2002 were merged into a common database. Demographic and medical data, including mortality and cancer incidence, were ascertained through linkages with nationwide, and essentially complete, population and health-care registers. The risk of cancer in exposed recipients relative to that in recipients who received blood from non-cancerous donors was estimated with multivariate Poisson regression, adjusting for potential confounding factors. FINDINGS: Of the 354 094 transfusion recipients eligible for this analysis, 12,012 (3%) were exposed to blood products from precancerous donors. There was no excess risk of cancer overall (adjusted relative risk 1.00, 95% CI 0.94-1.07) or in crude anatomical subsites among recipients of blood from precancerous donors compared with recipients of blood from non-cancerous donors. INTERPRETATION: Our data provide no evidence that blood transfusions from precancerous blood donors are associated with increased risk of cancer among recipients compared with transfusions from non-cancerous donors.
BACKGROUND: Although mechanisms for detection of short-term complications after blood transfusions are well developed, complications with delayed onset, notably transmission of chronic diseases such as cancer, have been difficult to assess. Our aim was to investigate the possible risk of cancer transmission from blood donors to recipients through blood transfusion. METHODS: We did a register-based retrospective cohort study of cancer incidence among patients who received blood from donors deemed to have a subclinical cancer at the time of donation. These precancerous donors were diagnosed with a cancer within 5 years of the donation. Data from all computerised blood bank registers in Sweden and Denmark gathered between 1968 and 2002 were merged into a common database. Demographic and medical data, including mortality and cancer incidence, were ascertained through linkages with nationwide, and essentially complete, population and health-care registers. The risk of cancer in exposed recipients relative to that in recipients who received blood from non-cancerous donors was estimated with multivariate Poisson regression, adjusting for potential confounding factors. FINDINGS: Of the 354 094 transfusion recipients eligible for this analysis, 12,012 (3%) were exposed to blood products from precancerous donors. There was no excess risk of cancer overall (adjusted relative risk 1.00, 95% CI 0.94-1.07) or in crude anatomical subsites among recipients of blood from precancerous donors compared with recipients of blood from non-cancerous donors. INTERPRETATION: Our data provide no evidence that blood transfusions from precancerous blood donors are associated with increased risk of cancer among recipients compared with transfusions from non-cancerous donors.
Authors: Lorenz R Rhomberg; Lisa A Bailey; Julie E Goodman; Ali K Hamade; David Mayfield Journal: Crit Rev Toxicol Date: 2011-06-02 Impact factor: 5.635
Authors: G Edgren; H Hjalgrim; K Rostgaard; V Dahl; K Titlestad; C Erikstrup; A Wikman; R Norda; A Majeed Journal: J Intern Med Date: 2018-04-25 Impact factor: 8.989
Authors: James R Cerhan; Eleanor Kane; Claire M Vajdic; Martha S Linet; Alain Monnereau; Leslie Bernstein; Silvia de Sanjose; Brian C-H Chiu; John J Spinelli; L Dal Maso; Yawei Zhang; Beth R Larrabee; Wendy Cozen; Alexandra G Smith; Jacqueline Clavel; Diego Serraino; Tongzhang Zheng; Elizabeth A Holly; Dennis D Weisenberger; Susan L Slager; Paige M Bracci Journal: Cancer Causes Control Date: 2019-06-04 Impact factor: 2.506
Authors: Gustaf Edgren; Mads Kamper-Jørgensen; Sandra Eloranta; Klaus Rostgaard; Brian Custer; Henrik Ullum; Edward L Murphy; Michael P Busch; Marie Reilly; Mads Melbye; Henrik Hjalgrim; Olof Nyrén Journal: Transfusion Date: 2010-02-12 Impact factor: 3.157
Authors: Steven Kleinman; Michael P Busch; Edward L Murphy; Hua Shan; Paul Ness; Simone A Glynn Journal: Transfusion Date: 2013-11-04 Impact factor: 3.157
Authors: Michaël Chassé; Lauralyn McIntyre; Alan Tinmouth; Jason Acker; Shane W English; Greg Knoll; Alan Forster; Nadine Shehata; Kumanan Wilson; Carl van Walraven; Robin Ducharme; Dean A Fergusson Journal: BMJ Open Date: 2015-01-19 Impact factor: 2.692
Authors: Natalie Urwyler; Sven Trelle; Lorenz Theiler; Peter Jüni; Lukas P Staub; Cedric Luyet; Lorenzo Alberio; Kay Stricker; Robert Greif Journal: Trials Date: 2009-11-23 Impact factor: 2.279
Authors: Martin C S Wong; Johnny Y Jiang; Jin-ling Tang; Augustine Lam; Hong Fung; Stewart W Mercer Journal: BMC Health Serv Res Date: 2008-06-25 Impact factor: 2.655